PT  - JOURNAL ARTICLE
AU  - Cazé, Ana Beatriz C
AU  - Cerqueira-Silva, Thiago
AU  - Bomfim, Adriele Pinheiro
AU  - de Souza, Gisley Lima
AU  - Andrade Azevedo, Amanda Canário
AU  - Aguiar Brasil, Michelle Queiroz
AU  - Rúbia Santos, Nara
AU  - Khouri, Ricardo
AU  - Dan, Jennifer
AU  - Bandeira, Antonio Carlos
AU  - de Goes Cavalcanti, Luciano Pamplona
AU  - Barral-Netto, Manoel
AU  - Prado Barral, Aldina Maria
AU  - Barbosa, Cynara Gomes
AU  - Boaventura, Viviane Sampaio
TI  - Prevalence and risk factors for long COVID after mild disease: a longitudinal study with a symptomatic control group
AID  - 10.1101/2022.09.15.22279958
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.15.22279958
4099  - http://medrxiv.org/content/early/2022/09/22/2022.09.15.22279958.short
4100  - http://medrxiv.org/content/early/2022/09/22/2022.09.15.22279958.full
AB  - Background There is limited data on the prevalence and risk factors for long COVID, with a shortage of prospective studies with appropriate control groups and adequate sample size. We therefore performed a prospective study to determine the prevalence and risk factors for long COVID.Methods We recruited patients age ≥ 15 years who were clinically suspected of having acute SARS-CoV-2 infection from September 2020 to April 2021. Nasopharyngeal swabs were collected for RT-PCR 3-5 days post symptom onset. Clinical and sociodemographic characteristics were collected using structured questionnaires from persons positive and negative for SARS-COV-2. Follow-up was performed by telephone interview to assess early outcomes and persistent symptoms. For COVID-19 cases, 5D-3L EuroQol questionnaire was used to assess the impact of symptoms on quality of life.Results We followed 814 participants (412 COVD-19 positive and 402 COVID-19 negative persons) of whom the majority (741 / 814) had mild symptoms. Both the COVID-19 positive and the COVID-19 negative groups had similar sociodemographic and clinical characteristics, except for the rate of hospitalization (15.8% vs 1.5%, respectively). One month after disease onset, 122 (29.6%) individuals reported residual symptoms in the COVID-19 positive group or the long COVID group versus 24 (6%) individuals in the COVID-19 negative group. In the long COVID group, fatigue, olfactory disorder, and myalgia were the most frequent symptoms which occurred in the acute phase. Compared to recovered patients, female sex, older age and having > 5 symptoms during the acute phase were risk factors for long COVID. Quality of life was evaluated in 102 out of 122 cases of long COVID with 57 (55.9%) reporting an impact in at least one dimension of the EuroQol 5D-3L questionnaire.Conclusion In this prospective study consisting predominantly of patients with mild disease, the persistence of symptoms after acute disease was highly associated with long COVID-19 (29.6% vs 6% of COVID negative group). The risk factors for long COVID were older age, female sex, and polysymptomatic acute disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: This study was supported by MCTI/CNPq/FNDCT/MS/SCTIE/Decit (no. 07/2020) MB-N, AB and VSB are research fellows from CNPq, the Brazilian National Research Council. T.C-S. is a PhD student at the Post-Graduation Program in Health Sciences-UFBA, which is supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil, finance code 001.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval and consent to participate: Informed consent was obtained from all participants. The Ethics in Research Committee of the Goncalo Moniz Research Center approved this study (approval no. 4.315.319/202).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailability of data and materials: The dataset generated and/or analyzed during the current study are not publicly available due to legal and ethical restrictions. Dataset are available upon request.STROBEStrengthening the Reporting of Observational Studies in EpidemiologyRT-PCRReverse Transcriptase Polymerase Chain ReactionREDCapResearch Electronic Data Capture softwareIGM/FIOCRUZGonçalo Moniz InstituteICUIntensive Care UnitSDStandard DeviationIQRInterquartile Range